FDA gives Sunshine Heart green light for pivotal U.S. trial

Sunshine Heart ($SSH) will launch a pivotal U.S. clinical trial by the end of this year for its C-Pulse heart assist implant, following unconditional approval from the FDA to move ahead. The Minnesota and Australian-based company wants to use its device to treat patients with Class III and ambulatory Class IV heart failure, and will gather data on how well the product can reduce re-hospitalization rates due to worsening heart failure. Plans call for evaluating 388 patients, half of which will be implanted with C-Pulse. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.